YONGAN PHARMACEUTICAL released its performance for the first three quarters, with a net profit attributable to the parent company of 25.4963 million yuan, a year-on-year decrease of 58.78%
According to the Zhitong Finance APP, YONGAN PHARMACEUTICAL released its third-quarter report for 2025. In the first three quarters, the company achieved an operating income of 577 million yuan, a year-on-year decrease of 6.72%. The net profit attributable to shareholders of the listed company was 25.4963 million yuan, a year-on-year decrease of 58.78%. The net profit attributable to shareholders of the listed company after deducting non-recurring gains and losses was 5.1844 million yuan, a year-on-year decrease of 86.17%
According to the Zhitong Finance APP, YONGAN PHARMACEUTICAL (002365.SZ) released its third-quarter report for 2025. In the first three quarters, the company achieved operating revenue of 577 million yuan, a year-on-year decrease of 6.72%. The net profit attributable to shareholders of the listed company was 25.4963 million yuan, a year-on-year decrease of 58.78%. The net profit attributable to shareholders of the listed company after deducting non-recurring gains and losses was 5.1844 million yuan, a year-on-year decrease of 86.17%
